Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

about

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Item

http://www.wikidata.org/entity/Q48339888

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

@en

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

@nl

type

Item

label

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

@en

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

@nl

prefLabel

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

@en

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

@nl

P1476

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases

@en

P2093

Chuanguo Guo

http://www.w3.org/2001/XMLSchema#string

Iqtida Ahmed Mirza

http://www.w3.org/2001/XMLSchema#string

Mingming Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaoxiao Yang

http://www.w3.org/2001/XMLSchema#string

Yiyuan Sun

http://www.w3.org/2001/XMLSchema#string

Yueyue Li

http://www.w3.org/2001/XMLSchema#string

P2860

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.

Systematic comparison of molecular conformations of H+,K+-ATPase reveals an important contribution of the A-M2 linker for the luminal gating.

Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review

High-throughput screening of potassium-competitive acid blockers.

Review article: the control of gastric acid and Helicobacter pylori eradication.

Guidelines for the diagnosis and management of gastroesophageal reflux disease.

Vonoprazan: first global approval.

Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

P2888

s10620-017-4866-6

P304

302-311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S10620-017-4866-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yan Qing Li

P577

2017-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29282636

http://www.w3.org/2001/XMLSchema#string